Literature DB >> 20512292

Oral drugs for hypertensive urgencies: systematic review and meta-analysis.

Luciana Mendes Souza1, Rachel Riera, Humberto Saconato, Adriana Demathé, Alvaro Nagib Atallah.   

Abstract

CONTEXT AND
OBJECTIVE: Hypertensive urgencies are defined as severe elevations in blood pressure without evidence of acute or progressive target-organ damage. The need for treatment is considered urgent but allows for slow control using oral or sublingual drugs. If the increase in blood pressure is not associated with risk to life or acute target-organ damage, blood pressure control must be implemented slowly over 24 hours. For hypertensive urgencies, it is not known which class of antihypertensive drug provides the best results and there is controversy regarding when to use antihypertensive drugs and which ones to use in these situations. The aim of this review was to assess the effectiveness and safety of oral drugs for hypertensive urgencies.
METHODS: This systematic review of the literature was developed at the Brazilian Cochrane Center, and in the Discipline of Emergency Medicine and Evidence-Based Medicine at the Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM), in accordance with the methodology of the Cochrane Collaboration.
RESULTS: Sixteen randomized clinical trials including 769 participants were selected. They showed that angiotensin-converting enzyme inhibitors had a superior effect in treating hypertensive urgencies, evaluated among 223 participants. The commonest adverse event for calcium channel blockers were headache (35/206), flushing (17/172) and palpitations (14/189). For angiotensin-converting enzyme inhibitors, the principal side effect was bad taste (25/38).
CONCLUSIONS: There is important evidence in favor of the use of angiotensin-converting enzyme inhibitors for treating hypertensive urgencies, compared with calcium channel blockers, considering the better effectiveness and the lower frequency of adverse effects (like headache and flushing).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20512292     DOI: 10.1590/s1516-31802009000600009

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  5 in total

1.  Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT).

Authors:  Alain Vuylsteke; Jean-Louis Vincent; Didier Payen de La Garanderie; Frederick A Anderson; Leigh Emery; Allison Wyman; Sophie Rushton-Smith; Joel M Gore
Journal:  Crit Care       Date:  2011-11-16       Impact factor: 9.097

Review 2.  The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.

Authors:  Hakuo Takahashi; Masamichi Yoshika; Yutaka Komiyama; Masato Nishimura
Journal:  Hypertens Res       Date:  2011-08-04       Impact factor: 3.872

3.  Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation.

Authors:  Ravi Venkatachelam Chitrapu; Pentakota Ramana Rao; Gangireddy Venkateswara Reddy
Journal:  J Pharmacol Pharmacother       Date:  2014-10

4.  Effects of 12-Week Supplementation of a Polyherbal Formulation in Old Adults with Prehypertension/Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Tian Shen; Guoqiang Xing; Jingfen Zhu; Yong Cai; Shuxian Zhang; Gang Xu; Yi Feng; Donghua Li; Jianyu Rao; Rong Shi
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-14       Impact factor: 2.629

5.  Pharmacologic Treatment of Hypertensive Urgency in the Outpatient Setting: A Systematic Review.

Authors:  Claudia L Campos; Charles T Herring; Asima N Ali; Deanna N Jones; James L Wofford; Augustus L Caine; Robert L Bloomfield; Janine Tillett; Karen S Oles
Journal:  J Gen Intern Med       Date:  2018-01-16       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.